KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

Hong, David S., Fakih, Marwan G., Strickler, John H., Desai, Jayesh, Durm, Gregory A., Shapiro, Geoffrey I., Falchook, Gerald S., Price, Timothy J. +26 more·2020·New England Journal of Medicine
DOI 10.1056/nejmoa1917239

Cited by (1,002)

Items 101–200 of 1,002

  1. Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen
    Andrew J. Poole, Vijaykumar Karuppiah, Annabelle Hartt, Jaafar N. Sleiman Haidar, Sylvie Moureau, Tomasz Dobrzycki, Conor Hayes, Christopher N. Rowley, J.C. Dias, Stephen J Harper et al. · 2022 · Nature Communications
  2. JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRAS <sup>G12C</sup> for the Treatment of Solid Tumors
    Lorthiois, Edwige, Gerspacher, Marc, Beyer, Kim S., Vaupel, Andrea, Leblanc, Catherine, Stringer, Rowan, Weiss, Andreas, Wilcken, Rainer, Guthy, Daniel A., Lingel, Andreas et al. · 2022 · Journal of Medicinal Chemistry
  3. Landscape of KRAS G12C , Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS -Mutated Cancers
    Mohamed E. Salem, Sherif Mohamed El-Refai, Wei Sha, Alberto Puccini, Axel Grothey, Thomas J. George, Jimmy J. Hwang, Bert H. O’Neil, Alexander S. Barrett, Kunal C. Kadakia et al. · 2022 · JCO Precision Oncology
  4. Cholangiocarcinoma 2026: status quo, unmet needs and priorities
    Jesús M. Bañales, Pedro M. Rodrigues, Silvia Affò, Jesper Bøje Andersen, Patricia Aspichueta, Luke Boulter, John A. Bridgewater, Diego Francesco Calvisi, Andrés Cárdenas, Vincenzo Cardinale et al. · 2025 · Nature Reviews Gastroenterology & Hepatology
  5. Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies
    Alberto D’Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello · 2020 · Cancers
  6. Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis—New insight and futuristic vision
    Xiao Lin Huang, Muhammad Imran Khan, Jing Wang, Rizwan Ali, Syed Wajahat Ali, Qurat ul ain Zahra, Ahsan Kazmi, Arbelo Lolai, Yü Huang, Alamdar Hussain et al. · 2021 · International Journal of Biological Macromolecules
  7. Immunotherapy in non-small cell lung cancer harbouring driver mutations
    Alfredo Addeo, Antonio Passaro, Umberto Malapelle, Giuseppe Luigi Banna, Vivek Subbiah, Alex Friedlaender · 2021 · Cancer Treatment Reviews
  8. Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes
    Jason C. Chang, Michael David Offin, Christina J. Falcon, David N. Brown, Brian R. Houck-Loomis, Fanli Meng, Vasilisa A. Rudneva, Helen H. Won, Sharon Amir, Joseph Montecalvo et al. · 2021 · Clinical Cancer Research
  9. Reversible lysine-targeted probes reveal residence time-based kinase selectivity
    Tangpo Yang, Adolfo Cuesta, Xiaobo Wan, Gregory B. Craven, Brad P. Hirakawa, Penney L. Khamphavong, Jeffrey R. May, John C. Kath, John D. Lapek, Sherry Niessen et al. · 2022 · Nature Chemical Biology
  10. Cell Type–Specific Adaptive Signaling Responses to KRASG12C Inhibition
    Solanki, Hitendra S., Welsh, Eric A., Fang, Bin, Izumi, Victoria, Darville, Lancia, Stone, Brandon, Franzese, Ryan, Chavan, Sandip, Kinose, Fumi, Imbody, Denis et al. · 2021 · Clinical Cancer Research
  11. Recent Advancements, Limitations, and Future Perspectives of the use of Personalized Medicine in Treatment of Colon Cancer
    Amit Dey, Abhijit Mitra, Surajit Pathak, Suhanya Veronica Prasad, Alexander Sun-Zhang, Hong Zhang, Xiao‐Feng Sun, Antara Banerjee · 2023 · Technology in Cancer Research & Treatment
  12. KRAS Inhibitor Resistance in <i>MET</i> -Amplified <i>KRAS</i> G12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms
    Suzuki, Shinichiro, Yonesaka, Kimio, Teramura, Takeshi, Takehara, Toshiyuki, Kato, Ryoji, Sakai, Hitomi, Haratani, Koji, Tanizaki, Junko, Kawakami, Hisato, Hayashi, Hidetoshi et al. · 2021 · Clinical Cancer Research
  13. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer
    Stanley I. Gutiontov, William Tyler Turchan, Liam Flinn Spurr, Sherin Juliet Rouhani, Carolina Soto Chervin, George Steinhardt, Angela M. Lager, Pankhuri Wanjari, Renuka Malik, Philip P. Connell et al. · 2021 · Scientific Reports
  14. Emerging evidence and treatment paradigm of non-small cell lung cancer
    Si‐Yang Maggie Liu, Mei-Mei Zheng, Yi Pan, Si‐Yang Maggie Liu, Yangqiu Li, Yi-Long Lung Cancer Wu · 2023 · Journal of Hematology & Oncology
  15. Combinatorial strategies to target RAS-driven cancers
    Naiara Perurena, Lisa Situ, Karen M. Cichowski · 2024 · Nature reviews. Cancer
  16. The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS
    Li, Chuanchuan, Vides, Alberto, Kim, Dongsung, Xue, Jenny Y., Zhao, Yulei, Lito, Piro · 2021 · Science
  17. Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition
    Tsai, Yihsuan S., Woodcock, Mark G., Azam, Salma H., Thorne, Leigh B., Kanchi, Krishna L., Parker, Joel S., Vincent, Benjamin G., Pecot, Chad V. · 2022 · Journal of Clinical Investigation
  18. Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
    Zhou, Caicun, Li, Chongyang, Luo, Libo, Li, Xin, Jia, Keyi, He, Ning, Mao, Shiqi, Wang, Wanying, Shao, Chuchu, Liu, Xinyu et al. · 2024 · Cancer Cell
  19. Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways
    Zhi Zhu, AJ Robert McGray, Weijian Jiang, Binfeng Lu, Paweł Kaliński, Zong Sheng Guo · 2022 · Molecular Cancer
  20. Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance
    Damien Reita, Lucile Pabst, Erwan Pencreach, Éric Guérin, Laurent Dano, Valérie Rimelen, Anne‐Claire Voegeli, Laurent D. Vallat, Céline Mascaux, Michèle Beau‐Faller · 2022 · Cancers
  21. Targeting KRAS in pancreatic cancer
    Sandra Stickler, BARBARA RATH, Gerhard Hamilton · 2024 · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
  22. CT-based Radiogenomic Analysis of Clinical Stage I Lung Adenocarcinoma with Histopathologic Features and Oncologic Outcomes
    Rocío Pérez-Johnston, José de Arimateia Batista Araújo-Filho, James G. Connolly, Raul Caso, Karissa A. Whiting, Kay See Tan, Jian Hua Zhou, Peter Gibbs, Natasha Rekhtman, Michelle S. Ginsberg et al. · 2022 · Radiology
  23. Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response
    Toni T. Seppälä, Jacquelyn W. Zimmerman, Reecha Suri, Haley Zlomke, Gabriel D. Ivey, Annamária Szabolcs, Christopher R. Shubert, John L. Cameron, William R. Burns, Kelly J. Lafaro et al. · 2022 · Clinical Cancer Research
  24. KRAS G12C–Mutant Non–Small Cell Lung Cancer
    Veluswamy, Rajwanth, Mack, Philip C., Houldsworth, Jane, Elkhouly, Ehab, Hirsch, Fred R. · 2021 · The Journal of Molecular Diagnostics
  25. Cancer research needs a better map
    Jesse S. Boehm, Mathew J. Garnett, David J. Adams, Hayley E. Francies, Todd R. Golub, William C. Hahn, Francesco Iorio, James M. McFarland, Leopold Parts, Francisca Vázquez · 2021 · Nature
  26. Massively parallel phenotyping of coding variants in cancer with Perturb-seq
    Ursu, Oana, Neal, James T., Shea, Emily, Thakore, Pratiksha I., Jerby-Arnon, Livnat, Nguyen, Lan, Dionne, Danielle, Diaz, Celeste, Bauman, Julia, Mosaad, Mariam Mounir et al. · 2022 · Nature Biotechnology
  27. MNK Inhibition Sensitizes <i>KRAS</i> -Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression
    Knight, John R.P., Alexandrou, Constantinos, Skalka, George L., Vlahov, Nikola, Pennel, Kathryn, Officer, Leah, Teodosio, Ana, Kanellos, Georgios, Gay, David M., May-Wilson, Sebastian et al. · 2021 · Cancer Discovery
  28. Breakthrough in targeted therapy for non-small cell lung cancer
    Ye Zhencong, Yongmei Huang, Jianhao Ke, Xiao Ming Zhu, Shuilong Leng, Hui Luo · 2020 · Biomedicine & Pharmacotherapy
  29. Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations
    Zhou, Chuan, Fan, Zisheng, Zhou, Zehui, Li, Yupeng, Cui, Rongrong, Liu, Chaoyi, Zhou, Guizhen, Diao, Xingxing, Jiang, Hualiang, Zheng, Mingyue et al. · 2022 · Journal of Medicinal Chemistry
  30. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
    Yousef, Abdelrahman, Yousef, Mahmoud, Chowdhury, Saikat, Abdilleh, Kawther, Knafl, Mark, Edelkamp, Paul, Alfaro-Munoz, Kristin, Chacko, Ray, Peterson, Jennifer, Smaglo, Brandon G. et al. · 2024 · npj Precision Oncology
  31. Unveiling the role of KRAS in tumor immune microenvironment
    Miao Xu, Xing Zhao, Ti Wen, Xiujuan Qu · 2024 · Biomedicine & Pharmacotherapy
  32. D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results
    Li, Ziming, Song, Zhengbo, Zhao, Yanqiu, Wang, Pingli, Jiang, Liyan, Gong, Yi, Zhou, Jianying, Jian, Hong, Dong, Xiaorong, Zhuang, Wu et al. · 2023 · Journal of Thoracic Oncology
  33. Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges
    Guoqiang Sun, Dawei Rong, Zhouxiao Li, Guangshun Sun, Fan Wu, Xiao Li, Hongyong Cao, Ye Cheng, Weiwei Tang, Yangbai Sun · 2021 · Frontiers in Cell and Developmental Biology
  34. Targeted therapy for lung cancer: Beyond EGFR and ALK
    Mercedes Herrera, Cristina Serrano‐Gómez, Helena Bote, Luis G Paz-Ares · 2023 · Cancer
  35. PROTAC therapy as a new targeted therapy for lung cancer
    Li, Jennifer W., Zheng, Guangrong, Kaye, Frederic J., Wu, Lizi · 2023 · Molecular Therapy
  36. Strategies to tackle RAS-mutated metastatic colorectal cancer
    Patelli, G., Tosi, F., Amatu, A., Mauri, G., Curaba, A., Patanè, D.A., Pani, A., Scaglione, F., Siena, S., Sartore-Bianchi, A. · 2021 · ESMO Open
  37. Pathogenesis of cancers derived from thyroid follicular cells
    James A. Fagin, Gnana Prakasam Krishnamoorthy, Iñigo Landa · 2023 · Nature reviews. Cancer
  38. The evolving landscape of tissue‐agnostic therapies in precision oncology
    Vivek Subbiah, Mohamed Alaa Gouda, Bettina Ryll, Howard A. Burris, Razelle Kurzrock · 2024 · CA A Cancer Journal for Clinicians
  39. Digestive cancers: mechanisms, therapeutics and management
    Tianzuo Zhan, Johannes Betge, Nadine Schulte, Lena Dreikhausen, Michael Hirth, Moying Li, Philip Weidner, Antonia Leipertz, Andreas Teufel, Matthias P A Ebert · 2025 · Signal Transduction and Targeted Therapy
  40. KRAS G12C Mutations in NSCLC: From Target to Resistance
    Alfredo Addeo, Giuseppe Luigi Banna, Alex Friedlaender · 2021 · Cancers
  41. A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS
    Xiaohua Duan, Tuo Zhang, Lingling Feng, Neranjan de Silva, Benjamin C. Greenspun, Xing Wang, Jenna E. Moyer, M. Laura Martin, Rohit Chandwani, Olivier Elemento et al. · 2023 · Cell stem cell
  42. Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling
    Zhang, Baoyuan, Zhang, Yan, Zhang, Jiangwei, Liu, Ping, Jiao, Bo, Wang, Zaiqi, Ren, Ruibao · 2021 · Advanced Science
  43. Anti-PD-(L)1 for KRAS-mutant advanced non-small–cell lung cancers: a meta-analysis of randomized–controlled trials
    Thierry Landre, Grégoire Justeau, Jean‐Baptiste Assié, Kader Chouahnia, Claire Davoine, Chérifa Taleb, CHRISTOS CHOUAID, Boris Duchemann · 2021 · Cancer Immunology Immunotherapy
  44. The Genomics of Colorectal Cancer in Populations with African and European Ancestry
    Parvathi A. Myer, Jessica K. Lee, Russell W. Madison, Kith Pradhan, Justin Y. Newberg, Carmen R. Isasi, Samuel J. Klempner, Garrett Michael Frampton, Jeffery S. Ross, Jeffrey M. Venstrom et al. · 2022 · Cancer Discovery
  45. An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations
    Jesse Boumelha, Sophie de Carné Trécesson, Emily K. Law, Pablo Romero-Clavijo, Matthew A. Coelho, Kevin W. Ng, Edurne Mugarza, Christopher Moore, Sareena Rana, Deborah R. Caswell et al. · 2022 · Cancer Research
  46. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
    Tang, Daolin, Kroemer, Guido, Kang, Rui · 2021 · Molecular Cancer
  47. Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer
    Joel Rivera‐Concepción, Dipesh Uprety, Alex A. Adjei · 2022 · Cancer Research and Treatment
  48. MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
    Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, Laura Soucek · 2024 · Signal Transduction and Targeted Therapy
  49. Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer
    Mohanty, Atish, Nam, Arin, Srivastava, Saumya, Jones, Jeff, Lomenick, Brett, Singhal, Sharad S., Guo, Linlin, Cho, Hyejin, Li, Aimin, Behal, Amita et al. · 2023 · Science Advances
  50. Epigenetic regulation in lung cancer
    Shahin Ramazi, Maedeh Dadzadi, Zahra Sahafnejad, Abdollah Allahverdi · 2023 · MedComm
  51. KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond
    Misako Nagasaka, Bindu Rani Potugari, Alexis Nguyen, Ammar W. Sukari, Asfar Sohail Azmi, Sai‐Hong Ignatius Ou · 2021 · Cancer Treatment Reviews
  52. Clinical Impact of Molecular Subtyping of Pancreatic Cancer
    Xu Zhou, Kai Hu, Peter J. Bailey, Christoph Springfeld, Susanne Roth, Roma Kurilov, Benedikt Brors, Thomas Mathias Gress, Malte Buchholz, Jingyu An et al. · 2021 · Frontiers in Cell and Developmental Biology
  53. Rational development of combination therapies for biliary tract cancers
    James J. Harding, Danny N. Khalil, Luca Fabris, Ghassan K. Abou‐Alfa · 2022 · Journal of Hepatology
  54. Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
    Éabha O’Sullivan, Anna Keogh, Brian Henderson, Stephen P. Finn, Steven G. Gray, Kathy A. Gately · 2023 · Cancers
  55. Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers
    Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski, Gintautas Vainorius, Neil J. Gibson, Irene C. Waizenegger, Daniel Gerlach, Martin Augsten, Fiona Spreitzer et al. · 2024 · Cancer Discovery
  56. KRAS in NSCLC: State of the Art and Future Perspectives
    Cascetta, Priscilla, Marinello, Arianna, Lazzari, Chiara, Gregorc, Vanesa, Planchard, David, Bianco, Roberto, Normanno, Nicola, Morabito, Alessandro · 2022 · Cancers
  57. Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance
    Thatikonda, Venu, Lyu, Hengyu, Jurado, Sabine, Kostyrko, Kaja, Bristow, Christopher A., Albrecht, Christoph, Alpar, Donat, Arnhof, Heribert, Bergner, Oliver, Bosch, Karin et al. · 2024 · Nature Cancer
  58. Therapeutics Targeting Mutant KRAS
    Kyaw Zin Thein, Amadeo B. Biter, David S. Hong · 2020 · Annual Review of Medicine
  59. Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review
    Marisol Huerta, Susana Roselló, Luis Sabater-Orti, Ana Ferrer, Noelia Tarazona, Desamparados Roda, Valentina Gambardella, Clara Alfaro‐Cervelló, Marina Garcés‐Albir, Andrès M.R. Cervantes et al. · 2021 · Cancers
  60. KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
    Mingying Xie, Xiaoling Xu, Yun Fan · 2021 · Frontiers in Oncology
  61. Immunotherapy in microsatellite instability metastatic colorectal cancer: Current status and future perspectives
    Rodrigo Motta, Santiago Cabezas-Camarero, Cesar Torres Mattos, Alejandro Riquelme, Ana Calle, Alejandro Figueroa, Miguel J. Sotelo · 2021 · Journal of Clinical and Translational Research
  62. Targeting KRAS: from metabolic regulation to cancer treatment
    Yanyan Shi, Huiling Zheng, Tianzhen Wang, Shengpu Zhou, Shiqing Zhao, Mo Li, Baoshan Cao · 2025 · Molecular Cancer
  63. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer
    Barbara L. Melosky, Paul Wheatley‐Price, Rosalyn Anne Juergens, Adrian G. Sacher, Natasha B. Leighl, Ming‐Sound Tsao, Parneet Kaur Cheema, Stephanie Leann Snow, Geoffrey Liu, Paul B. Card et al. · 2021 · Lung Cancer
  64. Drugging the Undruggable: Advances on RAS Targeting in Cancer
    Míriam Molina‐Arcas, Amit Samani, Julian Downward · 2021 · Genes
  65. Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib
    Joshua Michael Bauml, Bob T. Li, Vamsidhar Velcheti, Ramaswamy Govindan, Alessandra Curioni Fontecedro, Christophe Dooms, Toshiaki Takahashi, Andrew W. Duda, Justin Iver Odegaard, Fernando Cruz‐Guilloty et al. · 2021 · Lung Cancer
  66. Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes
    Palma, Gabriela, Khurshid, Faisal, Lu, Kevin, Woodward, Brian, Husain, Hatim · 2021 · npj Precision Oncology
  67. Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy
    Hattori, Takamitsu, Maso, Lorenzo, Araki, Kiyomi Y., Koide, Akiko, Hayman, James, Akkapeddi, Padma, Bang, Injin, Neel, Benjamin G., Koide, Shohei · 2023 · Cancer Discovery
  68. Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications
    Moritz Reese, Sameer Abdallah Dhayat · 2021 · Journal of Hematology & Oncology
  69. High-throughput evaluation of genetic variants with prime editing sensor libraries
    Samuel I. Gould, Alexandra N. Wuest, Kexin Dong, Grace A. Johnson, Alvin Hsu, Varun K. Narendra, Ondine Atwa, Stuart S. Levine, David R. Liu, Francisco J. Sánchez Rivera · 2024 · Nature Biotechnology
  70. Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins
    Alexander Chan, Rebecca M. Haley, Mohd Altaf Najar, David Gonzalez-Martinez, Lukasz J. Bugaj, George M. Burslem, Michael J. Mitchell, Andrew Tsourkas · 2024 · Nature Communications
  71. The tumour microenvironment in pancreatic cancer — new clinical challenges, but more opportunities
    Heng‐Chung Kung, Kevin Zheng, Jacquelyn W. Zimmerman, Lei Zheng · 2025 · Nature Reviews Clinical Oncology
  72. Targeting KRAS: The Elephant in the Room of Epithelial Cancers
    Valeria Merz, Marina Gaule, Camilla Zecchetto, Alessandro Cavaliere, Simona Casalino, Camilla Pesoni, Serena Contarelli, Fabio Sabbadini, Monica Bertolini, Domenico Mangiameli et al. · 2021 · Frontiers in Oncology
  73. Direct mapping of ligandable tyrosines and lysines in cells with chiral sulfonyl fluoride probes
    Ying Chen, Gregory B. Craven, Roarke A. Kamber, Adolfo Cuesta, Serhii Zhersh, Yurii S. Moroz, Michael Cory Bassik, Jack Taunton · 2023 · Nature Chemistry
  74. Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer
    Yu, Chune, Luo, Dan, Yu, Jing, Zhang, Min, Zheng, Xiaobo, Xu, Guangchao, Wang, Jiaxin, Wang, Huiling, Xu, Yufei, Jiang, Ke et al. · 2022 · Oncogene
  75. Mechanisms of Response and Tolerance to Active RAS Inhibition in <i>KRAS</i> -Mutant Non–Small Cell Lung Cancer
    Araujo, Haniel A., Pechuan-Jorge, Ximo, Zhou, Teng, Do, Minh Truong, Hu, Xin, Rojas Alvarez, Frank R., Salvatierra, Maria E., Ibarguen, Heladio P., Lee, Richard, Raghulan, Rashi et al. · 2024 · Cancer Discovery
  76. Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates
    Kalluri, Valerie S., Smaglo, Brandon G., Mahadevan, Krishnan K., Kirtley, Michelle L., McAndrews, Kathleen M., Mendt, Mayela, Yang, Sujuan, Maldonado, Ana S., Sugimoto, Hikaru, Salvatierra, Maria E. et al. · 2025 · Nature Communications
  77. In situ identification of cellular drug targets in mammalian tissue
    Zhengyuan Pang, Michael A. Schafroth, Daisuke Ogasawara, Yu Wang, Victoria Nudell, Neeraj K. Lal, Dong Uk Yang, Kristina Wang, Dylan M. Herbst, Jacquelyn Ha et al. · 2022 · Cell
  78. Biphasic regulation of osteoblast development via the ERK MAPK–mTOR pathway
    Jung‐Min Kim, Yeon-Suk Yang, Jaehyoung Hong, Sachin R. Chaugule, Hyonho Chun, Marjolein C. H. van der Meulen, Ren Xu, Matthew Blake Greenblatt, Jae‐Hyuck Shim · 2022 · eLife
  79. Targeting BRAF and RAS in Colorectal Cancer
    Hélène Bellio, Jean-David Fumet, François Ghiringhelli · 2021 · Cancers
  80. Genomic Landscape of Angiosarcoma: A Targeted and Immunotherapy Biomarker Analysis
    Andrea P. Espejo Freire, Andrew Elliott, Andrew Eric Rosenberg, Philippos Apolinário Costa, Priscila Barreto‐Coelho, Emily Jonczak, Gina Z. D’Amato, Ty K. Subhawong, Junaid Arshad, Julio Alexander Díaz-Pérez et al. · 2021 · Cancers
  81. Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor
    Yuesheng Zhang · 2023 · Pharmacological Reviews
  82. RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade
    Marie‐Julie Nokin, Alessia Mira, Enrico Patrucco, Biagio Ricciuti, Sophie Cousin, Isabelle Soubeyran, Sonia San José, Serena Peirone, Livia Caizzi, Sandra Vietti Michelina et al. · 2024 · Nature Communications
  83. The Landscape of PIK3CA Mutations in Colorectal Cancer
    Ioannis A. Voutsadakis · 2021 · Clinical Colorectal Cancer
  84. Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers
    Vito Amodio, Gianluca Mauri, Nicole Megan Reilly, Andrea Sartore Bianchi, Salvatore Siena, Alberto Bardelli, Giovanni Germano · 2021 · Cancers
  85. Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations
    Jaewon Choi, Scott P. Goulding, Brandon P. Conn, Christopher D. McGann, Jared L. Dietze, Jessica Kohler, Divya Lenkala, Antoine J Boudot, Daniel Rothenberg, Paul J. Turcott et al. · 2021 · Cell Reports Methods
  86. Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry
    Febe van Maldegem, Karishma Valand, Megan Cole, Harshil Patel, Mihaela Angelova, Sareena Rana, Emma Colliver, Katey S.S. Enfield, Nourdine Kabirou Bah, Gavin P. Kelly et al. · 2021 · Nature Communications
  87. Comprehensive Clinical and Molecular Characterization of <i>KRAS</i><sup>G12C</sup>-Mutant Colorectal Cancer
    Henry, Jason T., Coker, Oluwadara, Chowdhury, Saikat, Shen, John Paul, Morris, Van K., Dasari, Arvind, Raghav, Kanwal, Nusrat, Maliha, Kee, Bryan, Parseghian, Christine et al. · 2021 · JCO Precision Oncology
  88. MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities
    Kang Qin, Lingzhi Hong, Jianjun J. Zhang, Xiuning Le · 2023 · Cancers
  89. Mechanisms of alkaliptosis
    Fangquan Chen, Rui Kang, Jiao Liu, Daolin Tang · 2023 · Frontiers in Cell and Developmental Biology
  90. Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development—a narrative review
    Santarpia, Mariacarmela, Ciappina, Giuliana, Spagnolo, Calogera Claudia, Squeri, Andrea, Passalacqua, Maria Ilenia, Aguilar, Andrés, Gonzalez-Cao, Maria, Giovannetti, Elisa, Silvestris, Nicola, Rosell, Rafael · 2023 · Translational Lung Cancer Research
  91. Clinical applications of mass spectrometry‐based proteomics in cancer: Where are we?
    Emma L. Boys, Jia Liu, Phillip James Robinson, Roger R. Reddel · 2022 · PROTEOMICS
  92. CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy
    Joel W. Neal, Nick Pavlakis, Sang‐We Kim, Yasushi Goto, Sun Min Lim, Giannis Mountzios, Elena Fountzilas, Anastasia S. Mochalova, Daniel Christian Christoph, Alessandra Bearz et al. · 2024 · Journal of Clinical Oncology
  93. Multi-tiered chemical proteomic maps of tryptoline acrylamide–protein interactions in cancer cells
    Evert Njomen, Rachel E. Hayward, Kristen E. DeMeester, Daisuke Ogasawara, Melissa M. Dix, Tracey Nguyen, Paige Ashby, Gabriel M. Simon, Stuart L. Schreiber, Bruno N. Melillo et al. · 2024 · Nature Chemistry
  94. Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications
    Nadia Saoudi Gonzalez, Francesc Salvà, Javier Ros, Iosune Baraibar, Marta Rodríguez-Castells, Ariadna García, Adriana Alcaráz, Sharela Vega, Sergio Bueno, Josep M. Tabernero et al. · 2023 · Cancers
  95. The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy
    Niklas Sturm, Thomas Jens Ettrich, Lukas Perkhofer · 2022 · Cancers
  96. KRAS: the Achilles’ heel of pancreas cancer biology
    Kristina Drizyte‐Miller, Taiwo Talabi, Ashwin Somasundaram, Adrienne D. Cox, Channing J. Der · 2025 · Journal of Clinical Investigation
  97. KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
    Zining Zhang, Heng Zhang, Xiang Liao, Hsiang‐i Tsai · 2023 · Frontiers in Cell and Developmental Biology
  98. Compromised Outcomes in Stage IV Non–Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data
    Jeffrey Alan Scott, Jochen K. Lennerz, Melissa Lynne Johnson, Lucio Gordan, Robert H. Dumanois, Luca Quagliata, Lauren L. Ritterhouse, Federico Cappuzzo, Brandon Wang, Mei Xue et al. · 2023 · JCO Oncology Practice
  99. Assigning functionality to cysteines by base editing of cancer dependency genes
    Li, Haoxin, Ma, Tiantai, Remsberg, Jarrett R., Won, Sang Joon, DeMeester, Kristen E., Njomen, Evert, Ogasawara, Daisuke, Zhao, Kevin T., Huang, Tony P., Lu, Bingwen et al. · 2023 · Nature Chemical Biology
  100. Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer
    Iosune Baraibar, Oriol Mirallas, Nadia Saoudi Gonzalez, Javier Ros, Francesc Salvà, Josep M. Tabernero, Elena Élez · 2021 · Cancers